Condition
Japanese Patients With ALS
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT04254913Phase 1CompletedPrimary
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
NCT04176224Phase 1CompletedPrimary
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
Showing all 2 trials